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NEW TECHNOLOGIES
Abstract: This report presents a new and simple methodology for the synthesis of
multicomponent peptide vaccines, named the peptide crosslinked micelles (PCMs). The PCMs
are core shell micelles designed to deliver peptide antigens and immunostimulatory DNA to
antigen-presenting cells (APCs). They are composed of immunostimulatory DNA, peptide
antigen, and a thiopyridal derived poly(ethylene glycol)-polylysine block copolymer. The
peptide antigen acts as a crosslinker in the PCM strategy, which allows the peptide antigen to
be efficiently encapsulated into the PCMs and also stabilizes them against degradation by
serum components. Cell culture studies demonstrated that the PCMs greatly enhance the uptake
of peptide antigens into human dendritic cells.
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Introduction
Vaccines based on peptide antigens have tremendous therapeutic potential against
infectious diseases and tumors, in which peptide epitopes have been defined. Peptide
vaccines have been capable of generating protective immunity against infectious
diseases in animal models, and numerous clinical trials with peptide vaccines are in
progress (Shirai et al 1994; van Endert 2001; Hunziker et al 2002; Purcell et al 2003).
However, despite their promise, the first generation of peptide vaccines has performed
poorly in human clinical trials, partially due to drug delivery problems (Brander et al
1996; BenMohamed et al 2002). Delivering peptide vaccines has been challenging
because they consist of multiple components, such as peptide antigens and
immunostimulatory molecules. Although promising results have been obtained with
peptide vaccines composed of lipid conjugates and poly(D,L-lactic-co-glycolic acid)
microparticles, there is still a great need for the development of new peptide vaccine
delivery vehicles (Ertl et al 1996; Jackson et al 1997).
In this report, a new peptide vaccine delivery vehicle is presented that is designed
to simultaneously deliver peptide antigens and immunostimulatory molecules to
antigen-presenting cells (APCs). They are named peptide crosslinked micelles (PCMs)
and are composed of block copolymer micelles that encapsulate immunostimulatory
(ISS)-DNA in their cores and are crosslinked by peptide antigens through disulfide
linkages (Figure 1). The PCMs are based on the disulfide crosslinking strategy, using
thiolated poly(ethylene glycol)(PEG)-peptide block copolymers, pioneered by the
Kataoka (Kakizawa et al 1999; Miyata et al 2004) and Rice (Park et al 2002)
laboratories for the delivery of DNA.
Methods and results
The PCMs are synthesized by a two-step process that uses the peptide antigen as the
crosslinking agent for the micelles. In the first step, the block copolymer I is self-
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assembled with ISS-DNA to generate core shell micelles,
which have a core composed of thiopyridal groups
intermixed with ISS-DNA (Figure 1). This step is based on
work from the Katoaka laboratory using thiolated PEG-poly-
l-lysine (PLL) block copolymers and plasmid DNA
(Kakizawa et al 1999; Kakizawa et al 2001;
Miyata et al 2004). In the second step these micelles are
crosslinked by reaction of their thiopyridal groups with a
cysteine-modified antigenic peptide to generate a disulfide
crosslinked micelle that contains both peptide antigens and
ISS-DNA. Thus the antigenic peptide plays a dual role in
the PCMs: it acts as a crosslinker to enhance serum stability,
but is also the therapeutic that needs to be delivered.
Disulfide linkages are selectively reduced inside cells
because of the high glutathione (GSH) concentration
(10 mM intracellular GSH concentration versus 100 mM
extracellular concentration) (Kakizawa et al 1999; Park et
al 2002; Miyata et al 2004). Therefore, after phagocytosis,
the disulfide crosslinks in the PCMs should get reduced,
and encapsulated peptide antigens and ISS-DNA will be
released. After release, the peptide antigens will be processed
by enzymes in the APCs and presented to T cells (Craiu et
al 1997),
 while the released ISS-DNA will induce the APCs
to secrete the cytokines needed for effective T cell activation
and proliferation.
The block copolymer I (Figure 2) forms the scaffold of
the PCMs and is composed of a PEG chain (5 kDa)
connected to a poly(lysine-thiopyridal) block (degree of
polymerization = 20). PEG-poly-l-lysine (PEG-PLL) block
copolymers have been extensively used for the synthesis of
disulfide crosslinked micelles. For example, PEG-PLL has
been thiolated by the Katoaka laboratory through the
reaction of PEG-PLL with either N-succinimidyl 3-(2-
pyridyldithio)-propionamido (SPDP) or Trauts reagent
(Kakizawa et al 2001; Miyata et al 2004). In this report we
chose to synthesize the block copolymer I via a Michael
addition reaction between PEG-PLL (III) (Harada et al 1995)
and hydroxyl-ethyl thiopyridal acrylate (IV) (Figure 2),
because it introduces a thiopyridal group onto the block
copolymer while also preserving its positive charges.
A HIV peptide vaccine was synthesized using the PCM
strategy with the peptide CGCRIQRGPGRAFVTIGK
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Figure 1 Peptide crosslinked micelle design and synthesis. Step 1: immunostimulatory (ISS)-DNA and I (PEG-PLL, poly(ethylene glycol)-poly-l-lysine) are mixed to
form micelles (uncrosslinked micelle). Step 2: These micelles are then crosslinked with the peptide antigen (II) to generate a delivery system that can encapsulate both
immunostimulatory molecules and peptide antigens. After phagocytosis by antigen-presenting cells (APCs), the peptide crosslinked micelles release their components.
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Figure 2 Chemical structure and synthesis of poly(ethylene glycol)-poly-l-lysine (PEG-PLL)-thiopyridal (I).International Journal of Nanomedicine 2006:1(1) 99
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CGCG (II). The peptide II comes from the glycoprotein-
120 (GP-120) and contains the sequence RIQRGPGRAF
VTIGK, which is both a class I and II antigen (Belyakov et
al 1998; Berzofsky et al 1999). First, micelles were formed
between I and ISS-DNA by mixing 0.5 mg of I with 0.1 mg
of ISS-DNA (5-TCCATGACGTTCCTGACGTT-3) (charge
ratio 1:15 [+/–]) in 0.5 mL of 50 mM phosphate-buffered
saline (PBS). Dynamic light scattering of these micelles by
the cumulants method indicated that they had an average
diameter of 57.0 nm. These micelles were then crosslinked
by adding 0.1 mg of II to the micelles (equal molar ratio of
cysteines on II to thiopyridal groups on I). The peptide II
was incorporated into the micelles through a disulfide
exchange reaction.
The kinetics of the disulfide exchange reaction between
II and the micelles were quantified by UV absorbance at
342 nm (generated from the released thiopyridone). Figure 3
demonstrates that II reacts rapidly with the micelles. At an
equal molar ratio of cysteine to thiopyridal groups, more
than 90% of the cysteine groups of the peptide were
consumed within 20 minutes. After the peptide crosslinking,
the average size of the micelles decreased to 50.0 nm.
The stimuli-responsive release of II from the PCMs due
to the presence of GSH was investigated to determine if the
PCMs will release peptide antigens after phagocytosis. The
PCMs were incubated with different concentrations of GSH
for 24 hours in 50 mM pH 7.4 PBS buffer, and then analyzed
by high performance liquid chromatography (HPLC) to
determine the release of II. Figure 4 demonstrates that the
presence of GSH triggers the release of II. Incubation of
the PCMs with 10 mM GSH (intracellular levels) induced
the release of 71% of II, whereas incubation of the PCMs
with just buffer induced the release of only 10% of II.
A key advantage of the PCM strategy is that it generates
a crosslinked delivery system. This crosslinking should
stabilize the PCMs in vivo. For example, the Katoaka
laboratory demonstrated that plasmid DNA, encapsulated
in disulfide crosslinked PEG-polylysine micelles, is
protected against decomposition induced by polyelectrolyte
exchange reactions with charged proteins (Kakizawa et al
1999; Miyata et al 2004). The stability of the PCMs to
decomposition was investigated by mixing the negatively
charged polymer poly(vinyl sulfate) (PVS) with the PCMs.
This mixture was then analyzed by gel electrophoresis to
determine the quantity of ISS-DNA displaced by the PVS.
As a control, PVS was also incubated with uncrosslinked
micelles composed of just I and ISS-DNA. Figure 5a, lane
4, demonstrates that PVS can disrupt uncrosslinked micelles
composed of just ISS-DNA and I. In contrast, Figure 5a,
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Figure 4 Release of peptide antigen (II) from the peptide crosslinked micelles
(PCMs) in the presence of glutathione (GSH). Conditions: 50 mM phosphate
buffered saline buffer (pH = 7.4), 24 hours’ incubation, room temperature.
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Figure 3 Crosslinking reaction of cysteines on peptide antigen (II) with
thiopyridal group in micelles.
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Figure 5 (a) Stability of peptide crosslinked micelles and (b) glutathione
(GSH)-induced release of DNA from the peptide crosslinked micelles. Charge
ratio of DNA to poly(ethylene glycol)-poly-l-lysine (PEG-PLL)-thiopyridal (I) is
1:15 (–/+); 1 µg of DNA was loaded in each lane; molar ratio of sulfate in
poly(vinyl sulfate) (PVS) (Mw = 17 000) to phosphate in DNA is 6:1; molar ratio
of cysteine on peptide to thiopyridal group on I is 1:1. All samples were
incubated at room temperature for 24 hours, followed by gel electrophoresis
with low range ultra agarose gel in tris/acetic acid/EDTA buffer.
(a)
(b)
initial position
initial positionInternational Journal of Nanomedicine 2006:1(1) 100
Hao et al
lane 5, demonstrates that PVS cannot displace ISS-DNA
from the PCMs, presumably because the peptide cross-
linking prevents the PVS from diffusing into the micelles
and displacing the ISS-DNA. Importantly, after incubation
of the PCMs with intracellular concentrations of GSH, the
PCMs release encapsulated ISS-DNA in the presence of
PVS, demonstrating that the micelles should release their
contents after phagocytosis (Figure 5b, lanes 2 and 3).
The ability of the PCMs to protect encapsulated ISS-
DNA from degradation by serum nucleases was also
investigated. PCMs were synthesized (as described above)
and incubated with 10% serum for 12 hours. These PCMs
were then examined by gel electrophoresis to determine the
stability of the encapsulated ISS-DNA. As a control, ISS-
DNA by itself was incubated with serum. Figure 6
demonstrates that ISS-DNA, by itself, was completely
hydrolyzed in 10% serum (lane 2). In contrast, ISS-DNA
encapsulated in the PCMs was protected from serum
nucleases, presumably because of the effects of the
crosslinking (lane 3), which should prevent nucleases from
entering the micelle.
The PCMs have a size appropriate for phagocytosis by
antigen-presenting cells and should therefore efficiently
deliver peptide antigens into antigen-presenting cells. To
investigate if the PCMs are efficiently phagocytosed by
APCs, we constructed PCMs using a fluorescein (FITC)-
labeled crosslinking peptide, FITC-CGSIINFEKLGCG. The
PCMs were synthesized by first mixing 1.8 mg of I with
0.3 mg of ISS-DNA (charge ratio 15:1 (+/–)) in 0.5 mL of
50 mM PBS, generating micelles, which were then
crosslinked by addition of 2.1 mg of FITC-CGSIIN
FEKLGCG. These micelles were then incubated with human
monocyte-derived dendritic cells (MDDCs), generated as
previously described (Agrawal et al 2003), for 4 hours in
10% fetal calf serum (FCS)-containing media. Figure 7
demonstrates that dendritic cells incubated with PCMs
containing FITC-CGSIINFEKLGCG (10 µg/ml) internalize
approximately 7 times more FITC-CGSIINFEKLGCG than
dendritic cells incubated only with FITC-CGSIINFEKLGCG
(10 µg/ml). Thus the PCMs are capable of greatly enhancing
the delivery of peptide antigens into human dendritic cells.
Conclusions
The PCM strategy is a robust and simple strategy for the
development of peptide vaccine delivery vehicles. Any
peptide antigen can be potentially incorporated into the
PCMs; it simply has to be modified with extra cysteines.
The components of the PCMs are also biodegradable and
should be easily amenable for human applications. As a
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Figure 6 Protection of immunostimulatory (ISS)-DNA in peptide crosslinked
micelles against serum nucleases. Charge ratio of ISS-DNA to poly(ethylene
glycol)-poly-l-lysine (PEG-PLL)-thiopyridal (I) is 1:15 (–/+); 1 µg of DNA was
loaded in each lane; glutathione (GSH) (100 µM) was added to lane 3 to induce
release of encapsulated ISS-DNA. All samples were incubated with 10% serum
at room temperature for 12 hours.
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Figure 7 Efficient uptake of peptide crosslinked micelles (PCMs) containing
fluorescein (FITC)-CGSIINFEKLGCG by human monocyte-derived dendritic
cells (MDDCs). MDDCs were pulsed with either (a) FITC-CGSIINFEKLGCG
(10 g/ml) or (b) PCMs containing FITC-CGSIINFEKLGCG (10 g/ml) for 4 hours
in 10% fetal calf serum (FCS)-containing media. Cells were analyzed by flow
cytometry for the mean fluorescence intensity (MFI) of fluorescein. Results are
representative of three separate experiments. The shaded region is the
autofluorescence of MDDCs incubated in just plain FCS-containing media; the
dark line is the fluorescence of MDDCs incubated with the fluorescein-
containing compounds.International Journal of Nanomedicine 2006:1(1) 101
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result, the PCMs should find numerous applications in
vaccine development.
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Appendices
Appendix 1: Materials
ε-(benzyloxycarbonyl)-L-lysine was purchased from
Novabiochem (San Diego, CA, USA) and α-methoxy-ω-
amino-poly(ethylene glycol) (PEG, Mw = 5000) was
purchased from NEKTAR Transforming Therapeutics (San
Carlos, CA, USA). The immunostimulatory (ISS)-DNA,
with the sequence of 5-TCCATGACGTTCCTGACGTT-3,
was purchased from Integrated DNA Technologies
(Coralville, IA, USA). Agarose was purchased from Bio-
Rad (Hercules, CA, USA), methanesulfonic acid was
purchased from Acros (Hampton, NH, USA), anisole and
triphosgene were purchased from TCI America (Portland,
OR, USA), 5,5´-dithio-bis(2-nitrobenzoic acid) (Ellman’s
Reagent) was purchased from Calbiochem (San Diego, CA,
USA), and 2,2-dithiodipyridine was purchased from Fluka
(SG Switzerland). Sodium hydroxide, potassium hydroxide,
sodium phosphate monobasic, and acetonitrile were
purchased from Fisher Scientific (Hampton, NH, USA).
L-glutathione (GSH), dithiothreitol (DTT), poly(vinyl
sulfate potassium salt) (PVS, Mw = 17 000), acetic acid,
trifluoroacetic acid, 2-mercaptoethanol, dichloromethlylene,
tetrahydronfuran (THF), and N,N-dimethylformamide
(DMF) were purchased from Sigma-Aldrich (St Louis, MO,
USA). THF and DMF were doubly distilled before use. The
peptide CGCRIQRGPGRAFVTIGKCGCG was synthesized
at the Petit Institute for Bioengineering and Bioscience’s
core facility on a 433A Peptide Synthesizer, Applied
Biosystems (Foster City, CA 94404, USA), and was purified
by HPLC (Column: Discovery HS C18, made by Supelco;
Hewlett Packard Series 1090 Liquid Chromatograph). (5-
carboxyfluorescein)-CGSIINFEKLGCG was synthesized
by SynPep Corporation (Dublin, CA, USA).
Figure A1 Proton nuclear magnetic resonance (
1H NMR) spectra of poly(ethylene glycol)-poly-l-lysine-thiopyridal in D2O.International Journal of Nanomedicine 2006:1(1) 102
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Appendix 2: Synthesis of poly(ethylene
glycol)-poly-l-lysine-thiopyridal (I)
44 µmol of poly(ethylene glycol)-poly-l-lysine (PEG-PLL)
(III), synthesized according to Harada and Kataoka (1995),
with PEG = 5 kDa and poly-l-lysine = 5 kDa, was dissolved
in 1 mL of N,N-dimethylformamide (DMF) in a 5 mL
round-bottom flask, fitted with a stir bar (overnight stirring
at room temperature was required to completely dissolve
the polymer). 415 µmol of hydroxyl-ethyl thiopyridal
acrylate (IV) and 58 µl of triethylamine were then added to
the PEG-PLL solution and the reaction was allowed to run
for 24 hours at room temperature (see Figure 2). The product
was isolated by precipitating the reaction solution into
15 mL of ice cold diethyl ether. The yield was 88.2%. The
product was analyzed by proton nuclear magnetic resonance
(
1H NMR) spectroscopy in D2O. The spectra are shown in
Figure A1. The percentage of amines alkylated was
determined by comparing the peak intensity ratio of pyridine
protons (–NC5H4: δ = 7.101 ppm, 7.629 ppm, 8.187 ppm)
versus  α,β,γ-methylene protons of poly-l-lysine
(–CH2CH2CH2: δ = 1.122 ppm, 1.285 ppm, 1.553 ppm). This
comparison indicated that 100% of the amines had been
reacted.
Appendix 3: Dynamic light scattering
analysis of peptide crosslinked micelles
A 50 mM phosphate-buffered saline (PBS) buffer solution,
at pH 7.4, containing 0.06 mg/mL of I and 20 µg/mL of
immunostimulatory (ISS)-DNA was made and filtered
through a 200 nm syringe filter. This solution was then
analyzed by dynamic light scattering (DLS) (Zetasizer Nano
ZS, Malvern Instruments Ltd, Worcestershire, UK), using
the cumulant method. The size and the size distribution of
the uncrosslinked micelles are shown in Figure A2. This
solution was then crosslinked by adding 0.12 mg of II. After
3 hours of reaction the solution was analyzed by DLS as
described above. The size and the size distribution of the
crosslinked micelles are shown in Figure A3.
Appendix 4: UV analysis of crosslinking
reaction between II and block
copolymer micelles
Block copolymer micelles were formed between I and ISS-
DNA by mixing 0.5 mg of I with 0.1 mg of ISS-DNA
(representing a 15:1 amine to phosphate ratio) in 0.5 mL of
50 mM PBS buffer (pH 7.4), in an Eppendorf tube. After
incubation for 2 hours at room temperature, 0.1 mg of II
(representing a 1:1 cysteine to thiopyridal ratio) was added
to the micelles. The crosslinking reaction between the
cysteines on II with the thiopyridal groups in the micelles
was determined by UV analysis at 342 nm (representing the
released thiopyridone). The UV spectra of representative
samples are shown in Figure A4. The percentage of cysteine
groups reacted was determined by the following formula
12
0
ABS ABS
reacted peptide (%) 100%
ABS
−
=×
where: ABS1 = UV absorption at 342 nm for the peptide-
crosslinked micelles reaction (solid circles in Figure A4);
ABS2 = UV absorption at 342 nm for the uncrosslinked
micelles, without peptide (open squares in Figure A4);
ABSo = UV absorption at 342 nm when all of the
thiopyridone groups have been reacted (by addition of
dithiothreitol) (open circles in Figure A4).
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Figure A2 Size distribution of the uncrosslinked micelles.
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Figure A3 Size distribution of the peptide crosslinked micelles.International Journal of Nanomedicine 2006:1(1) 103
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Appendix 5: Generation of human
dendritic cells and dendritic cell uptake
Generation of human monocyte-derived dendritic
cells (MDDCs)
CD14+ monocytes were enriched from peripheral blood
mononuclear cells using an enrichment step, and cultured
in six-well plates (1 × 10
6 per well) for 6 days with
recombinant human granulocyte/macrophage colony-
stimulating factor at 100 ng·ml
–1 (PeproTech, Rocky Hill,
NJ, USA) plus recombinant human IL-4 at 20 ng·ml
–1
(PeproTech). At day 6, the cultures consisted uniformly of
CD1a
+ CD14
–, HLA-DR
+ CD11c
+ cells, which were
negative for CD83, the human dendritic cell maturation
marker, and expressed intermediate levels of co-stimulatory
molecules as CD86.
Pulsing of human MDDCs and analysis
On day 6, 5 × 10
5 MDDCs were pulsed with 10 µg/mL of
FITC-CGSIINFEKLGCG peptide or FITC-CGSIINFEK
LGCG crosslinked micelles in DMEM medium sup-
plemented with 10% fetal calf serum for 4 hours at 37 °C in
96-well round-bottom plates (Corning, Acton, MA, USA).
Cells were washed 3 times and stained with HLA-DR
antibody (BD Pharmingen, San Diego, CA, USA). HLA-
DR+ cells were analyzed on FACScalibur (BD) flow
cytometer and the mean fluorescence intensity of fluorescein
was estimated using Flow-Jo software (TreeStar Inc,
Ashland, OR, USA).
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Figure A4 UV analysis for the reaction of cysteine on peptide with
thiopyridine in micelles.
Abbreviations: DTT, dithiothreitol.
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